Vedolizumab en el tratamiento de la enfermedad de Crohn

Gisbert, 2002, Questions and answers on the role of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease, Gastroenterol Hepatol., 25, 401, 10.1016/S0210-5705(02)70275-6 Chaparro, 2013, Safety of thiopurine therapy in inflammatory bowel disease: Long-term follow-up study of 3931 patients, Inflamm Bowel Dis., 19, 1404, 10.1097/MIB.0b013e318281f28f Gonzalez-Lama, 2012, Methotrexate in inflammatory bowel disease: A multicenter retrospective study focused on long-term efficacy and safety. The Madrid experience, Eur J Gastroenterol Hepatol., 24, 1086, 10.1097/MEG.0b013e3283556db5 Gomollon, 2014, Reccomendations of the Spanish Working Group on Crohn's disease and ulcerative colitis (GETECCU) on the use of methotrexate in inflammatory bowel diseases, Gastroenterol Hepatol. Domenech, 2008, Long-term methotrexate for Crohn's disease: Safety and efficacy in clinical practice, J Clin Gastroenterol., 42, 395, 10.1097/MCG.0b013e31802e6875 Cabriada, 2013, Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of anti-tumor necrosis factor drugs in inflammatory bowel disease, Gastroenterol Hepatol., 36, 127, 10.1016/j.gastrohep.2013.01.002 Ben-Horin, 2011, Review article: Loss of response to anti-TNF treatments in Crohn's disease, Aliment Pharmacol Ther., 33, 987, 10.1111/j.1365-2036.2011.04612.x Cohen, 2014, Biologic therapies in inflammatory bowel disease, Transl Res., 10.1016/j.trsl.2014.01.002 Ford, 2011, Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis, Am J Gastroenterol., 106, 644, 10.1038/ajg.2011.73 Chaparro, 2012, Intensification of infliximab therapy in Crohn's disease: Efficacy and safety, J Crohns Colitis., 6, 62, 10.1016/j.crohns.2011.07.005 Chaparro, 2011, Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose escalation in patients losing response, J Clin Gastroenterol., 45, 113, 10.1097/MCG.0b013e3181ebaef9 Colombel, 2009, Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: Results from the CHARM trial, Am J Gastroenterol., 104, 1170, 10.1038/ajg.2009.59 Gisbert, 2009, Loss of response and requirement of infliximab dose intensification in Crohn's disease: A review, Am J Gastroenterol., 104, 760, 10.1038/ajg.2008.88 Hanauer, 2002, Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial, Lancet., 359, 1541, 10.1016/S0140-6736(02)08512-4 Krishnareddy, 2014, When combination therapy isn’t working: Emerging therapies for the management of inflammatory bowel disease, World J Gastroenterol., 20, 1139, 10.3748/wjg.v20.i5.1139 Allen, 2013, Moving towards disease modification in inflammatory bowel disease therapy, Curr Opin Gastroenterol., 29, 397, 10.1097/MOG.0b013e3283622914 Chaparro, 2013, New advances in the treatment of inflammatory bowel disease, Gastroenterol Hepatol., 36, 21, 10.1016/S0210-5705(13)70050-5 Lowenberg, 2013, Novel targets for inflammatory bowel disease therapeutics, Curr Gastroenterol Rep., 15, 311, 10.1007/s11894-012-0311-3 Mozaffari, 2014, New biologic therapeutics for ulcerative colitis and Crohn's disease, Expert Opin Biol Ther., 14, 583, 10.1517/14712598.2014.885945 Reenaers, 2010, Current directions of biologic therapies in inflammatory bowel disease, Therap Adv Gastroenterol., 3, 99, 10.1177/1756283X09356872 Rietdijk, 2013, Recent developments in the treatment of inflammatory bowel disease, J Dig Dis., 14, 282, 10.1111/1751-2980.12048 Sandborn, 2012, The future of inflammatory bowel disease therapy: Where do we go from here?, Dig Dis., 30, 140, 10.1159/000342742 Cominelli, 2013, Inhibition of leukocyte trafficking in inflammatory bowel disease, N Engl J Med., 369, 775, 10.1056/NEJMe1307415 Fiorino, 2010, Leukocyte traffic control: A novel therapeutic strategy for inflammatory bowel disease, Expert Rev Clin Immunol., 6, 567, 10.1586/eci.10.40 Ghosh, 2012, Inhibition of selective adhesion molecules in treatment of inflammatory bowel disease, Int Rev Immunol., 31, 410, 10.3109/08830185.2012.690794 Lobaton, 2014, Review article: Anti-adhesion therapies for inflammatory bowel disease, Aliment Pharmacol Ther., 39, 579, 10.1111/apt.12639 McLean, 2012, Vedolizumab for the treatment of ulcerative colitis and Crohn's disease, Immunotherapy., 4, 883, 10.2217/imt.12.85 Mosli, 2014, T-cell trafficking and anti-adhesion strategies in inflammatory bowel disease: Current and future prospects, Drugs., 74, 297, 10.1007/s40265-013-0176-2 Thomas, 2012, Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis, Inflammopharmacology., 20, 1, 10.1007/s10787-011-0104-6 Tilg, 2010, Vedolizumab, a humanized mAb against the alpha4beta7 integrin for the potential treatment of ulcerative colitis and Crohn's disease, Curr Opin Investig Drugs., 11, 1295 Kempster, 2014, alpha4beta7 integrin: Beyond T cell trafficking, Gut., 63, 1377, 10.1136/gutjnl-2013-305967 Targan, 2007, Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial, Gastroenterology., 132, 1672, 10.1053/j.gastro.2007.03.024 Targan, 1997, A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group, N Engl J Med., 337, 1029, 10.1056/NEJM199710093371502 Fedyk, 2012, Exclusive antagonism of the alpha4 beta7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates, Inflamm Bowel Dis., 18, 2107, 10.1002/ibd.22940 Rezaie, 2014, Vedolizumab, a gut-specific monoclonal antibody, renews hope for an alternative to anti-TNF therapy in inflammatory bowel diseases, Ann Gastroenterol., 27, 179 Wyant, 2013, In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes, MAbs., 5, 842, 10.4161/mabs.26392 Gerner, 2013, B lymphocytes in inflammatory bowel diseases: Lessons from clinical trials, Dig Dis., 31, 328, 10.1159/000354687 Herrlinger, 2014, Therapeutic peptides in inflammatory bowel disease, Expert Opin Biol Ther., 10.1517/14712598.2014.880109 Poole, 2014, Vedolizumab: First global approval, Drugs., 74, 1293, 10.1007/s40265-014-0253-1 Rosario, 2014, Population pharmacokinetic modelling of vedolizumab in patients with ulcerative colitis or Crohn's disease, J Crohns Colitis., 8, S225, 10.1016/S1873-9946(14)60505-5 Milch, 2013, Vedolizumab, a monoclonal antibody to the gut homing alpha4beta7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype, J Neuroimmunol., 264, 123, 10.1016/j.jneuroim.2013.08.011 Dirks, 2014, Population pharmacokinetic modeling of vedolizumab in patients with ulcerative colitis or Crohn's disease, Gastroenterology., 146, 10.1016/S0016-5085(14)62140-5 Parikh, 2012, Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose-ranging study, Inflamm Bowel Dis., 18, 1470, 10.1002/ibd.21896 Jovani, 2013, Vedolizumab for the treatment of IBD: A selective therapeutic approach targeting pathogenic a4b7 cells, Curr Drug Targets., 14, 1433, 10.2174/13894501113146660206 Wang, 2009, The effect of α4β7 blockade on lymphocyte trafficking in the acute injury colitis model, Gastroenterology., 136, A Vedolizumab Ficha técnica. [consultado 15 Oct 2014]. Disponible en: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/002782/WC500168528.pdf Sands, 2014, Effects of increased vedolizumab dosing frequency on disease activity in ulcerative colitis and Crohn's disease, United European Gastroenterology Journal, 2, A67 Sandborn, 2013, Vedolizumab as induction and maintenance therapy for Crohn's disease, N Engl J Med., 369, 711, 10.1056/NEJMoa1215739 Sands, 2014, Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed, Gastroenterology., 147, 618, 10.1053/j.gastro.2014.05.008 Parikh, 2013, Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease, Inflamm Bowel Dis., 19, 1691, 10.1097/MIB.0b013e318281f538 Hanauer, 2014, Long-term efficacy of vedolizumab therapy for Crohn's disease, United European Gastroenterology Journal, 2, A66 Hanauer, 2013, Efficacy of vedolizumab in Crohn's disease by prior treatment failure in Gemini II, a randomized, placebo-controlled, double-blind, multicenter study, Gastroenterology., 144, 10.1016/S0016-5085(13)62854-1 Sandborn, 2014, Effects of continued vedolizumab therapy for Crohn's disease in week 6 induction therapy nonresponders, Gastroenterology., 146, 10.1016/S0016-5085(14)62132-6 Sandborn, 2014, Efficacy of continued vedolizumab therapy in patients with Crohn's disease who did not respond to vedolizumab induction therapy at week 6, J Crohns Colitis, 8, S274, 10.1016/S1873-9946(14)60617-6 Feagan, 2013, Vedolizumab as induction and maintenance therapy for ulcerative colitis, N Engl J Med., 369, 699, 10.1056/NEJMoa1215734 Colombel, 2013, Integrated safety analysis of vedolizumab for the treatment of ulcerative colitis or Crohn's disease, Gastroenterology., 144, 10.1016/S0016-5085(13)60410-2 Colombel, 2013, Long-term safety of vedolizumab for the treatment of ulcerative colitis or Crohn's disease, Am J Gastroenterol., 108, S502, 10.14309/00000434-201310001-01674 Colombel, 2014, Safety of vedolizumab alone or with concomitant corticosteroids and/or immunosuppressants in patients with ulcerative colitis or Crohn's disease, United European Gastroenterology Journal, 2, A82 Govani, 2013, Anti-adhesion therapies and the rule of 3 for rare events, Am J Gastroenterol., 108, 1831, 10.1038/ajg.2013.141 Haanstra, 2013, Antagonizing the alpha4beta1 integrin, but not alpha4beta7, inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis, J Immunol., 190, 1961, 10.4049/jimmunol.1202490 Herold, 2012, Hemianopia and visual loss due to progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis, Clin Ophthalmol., 6, 1131 Cordioli, 2014, Early detection and favourable outcome of natalizumab-related progressive multifocal leukoencephalopathy (PML) in two multiple sclerosis patients, Neurol Sci., 1 Parikh, 2009, Gastrointestinal selectivity of vedolizumab (MLN0002), a humanized monoclonal antibody to α 4β 7 integrin, J Crohn Colitis., 3, S62, 10.1016/S1873-9946(09)60157-4 Fedyk, 2011, The gastrointestinal-selective biologic vedolizumab does not impair immune surveillance of the central nervous system in non-human primates, J Crohns Colitis, 5, S1 Feagan, 2008, Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin, Clin Gastroenterol Hepatol., 6, 1370, 10.1016/j.cgh.2008.06.007 Gisbert, 2015, Systematic review with Meta-analysis: the efcacy of a second anti-TNF in patients with inammatory bowel disease whose previous anti-TNF treatment has failed, Aliment Pharmacol Ther., 10.1111/apt.13083 Gisbert, 2015, Use of a third anti-TNF after failure of two previous anti-TNFs in patients with inflammatory bowel disease: is it worth it?, Scand J Gastroenterol., 10.3109/00365521.2014.928901